更新于：2024-12-14
Cefditoren Pivoxil
头孢托仑酯
更新于：2024-12-14
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1994-04-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H28N6O7S3 |
InChIKeyAFZFFLVORLEPPO-UVYJNCLZSA-N |
CAS号117467-28-4 |
关联
20
项与 头孢托仑酯 相关的临床试验头孢托仑匹酯颗粒在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹/餐后生物等效性试验研究
头孢托仑匹酯颗粒在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性试验
头孢托仑匹酯片在健康人体内的生物等效性试验
100 项与 头孢托仑酯 相关的临床结果
登录后查看更多信息
100 项与 头孢托仑酯 相关的转化医学
登录后查看更多信息
100 项与 头孢托仑酯 相关的专利（医药）
登录后查看更多信息
258
项与 头孢托仑酯 相关的文献（医药）2025-01-01CONGENITAL ANOMALIES
A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan
Article
作者: Hayashi, Masahiro ; Nakayama, Takeo ; Nakajima, Ken ; Saito, Yoshiyuki ; Obara, Taku ; Takahashi, Kunihiko ; Suzuki, Naoto ; Murashima, Atsuko ; Toyama, Akira ; Goto, Mikako ; Honma, Mariko ; Yamane, Ritsuko
Abstract:
We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.
2024-12-01POULTRY SCIENCE
Effects of cardamonin on the growth performance, intestinal barrier function and intestinal microbiota of Danzhou chickens under heat stress
Article
作者: Shi, Liguang ; Jiang, Haoran ; Xun, Wenjuan ; Hou, Guanyu ; Deng, Tanjie
The aim of this study was to investigate the effects of cardamonin (CDN) on the growth performance, intestinal mucosal barrier function and intestinal microbiota of Danzhou chickens under heat stress. A total of 200 one-day-old female Danzhou chickens were randomly divided into 5 groups. The daytime temperature of heat stress (HS) was set at 36 ± 2°C, and the nighttime temperature was kept the same as in the control (CON) group at 25 ± 2°C. The formal experiment lasted for 21 d. The CON and HS groups were fed a basal diet, whereas the L-CDN, M-CDN, and H-CDN groups received a basal diet supplemented with 50, 100, and 200 mg/kg CDN, respectively. Compared with the HS group, the CDN group presented a significantly greater average daily gain (ADG) (P < 0.001) but a significantly lower feed-to-gain ratio (F/G) (P = 0.007). CDN supplementation also increased the villus height (VH) and the ratio of the villus height to crypt depth (V/C) (P < 0.001) and reduced intestinal permeability by increasing expression of the ZO-1 (P < 0.001), Occludin (P < 0.001), and Claudin-1 (P = 0.034) proteins and decreasing the content of D-lactic acid (D-LA) and the activity of diamine oxidase (DAO) in serum (P < 0.001). Additionally, CDN reduced the levels of the intestinal mucosal inflammatory factors (IL-1β (P = 0.031), IL-6 (P = 0.003), and TNF-α (P = 0.014)) while upregulating IL-10 (P < 0.001). Furthermore, it increased the total antioxidant capacity (T-AOC) (P = 0.004) and catalase (CAT) activity (P < 0.001) and reduced the malondialdehyde (MDA) content (P = 0.017), effectively reducing intestinal oxidative stress and inflammatory reactions. Expression of the Nrf2 pathway-related proteins Nrf2 (P = 0.012), HO-1 (P = 0.008), and NQO1 (P = 0.003) was also increased by CDN. Moreover, feeding CDN increased the proportion of beneficial bacteria such as Firmicutes and Bacteroidetes but decreased the proportion of harmful bacteria such as Proteobacteria, thus protecting the intestinal barrier. In summary, 200 mg/kg CDN in the diet improved growth performance, enhanced intestinal barrier function and improved intestinal flora disorders in heat stress-induced Danzhou chickens, which may be related to the Nrf2/NQO1 signaling pathway.
2024-11-01MICROBES AND INFECTION
Characterization and dynamics of intestinal microbiota in patients with Clostridioides difficile colonization and infection
Article
作者: Wang, Yuan ; Zhang, Shuntian ; Zhou, Yanzi ; Zhou, Kai ; Xiao, Tingting ; Lv, Tao ; Kong, Xiaoyang ; Chi, Xiaohui ; Cai, Hongliu ; Chen, Yunbo ; Shen, Ping ; Guo, Lihua ; Xiao, Yonghong
Gut microbiota dysbiosis increases the susceptibility to Clostridioides difficile infection (CDI). In this study, we monitored C. difficile colonization (CDC) patients from no CDC status (CDN) to CDC status (CDCp) and CDI patients from asymptomatic status before CDI (PRECDI), CDI status (ONCDI), to asymptomatic status after CDI (POSTCDI). Based on metagenomic sequencing, we aimed to investigate the interaction pattern between gut microbiota and C. difficile. There was no significant difference of microbiota diversity between CDN and CDCp. In CDCp, Bacteroidetes and short-chain fatty acid (SCFA)-producing bacteria increased, with a positive correlation between SCFA-producing bacteria and C. difficile colonization. Compared with PRECDI, ONCDI and POSTCDI showed a significant decrease in microbiota diversity, particularly in Bacteroidetes and SCFA-producing bacteria, with a positive correlation between opportunistic pathogen and C. difficile. Fatty acid metabolism, and amino acid biosynthesis were enriched in CDN, CDCp, and PRECDI, while bile secretion was enriched in ONCDI and POSTCDI. Microbiota and metabolic pathways interaction networks in CDN and CDCp were more complex, particularly pathways in fatty acid and bile acid metabolism. Increasing of Bacteroidetes and SCFA-producing bacteria, affecting amino acid and fatty acid metabolism, is associated with colonization resistance to C. difficile and inhibiting the development of CDI.
100 项与 头孢托仑酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社区获得性肺炎 | 美国 | 2002-08-21 | |
| 慢性支气管炎 | 美国 | 2001-08-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2001-08-29 | |
| 咽炎 | 美国 | 2001-08-29 | |
| 扁桃体炎 | 美国 | 2001-08-29 | |
| 细菌感染 | 日本 | 1994-04-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性膀胱炎 | 临床3期 | 希腊 | 2007-11-01 | |
| 急性膀胱炎 | 临床3期 | 西班牙 | 2007-11-01 | |
| 泌尿道感染 | 临床3期 | 希腊 | 2007-11-01 | |
| 泌尿道感染 | 临床3期 | 西班牙 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用